Toll-like receptors and their role in carcinogenesis and anti-tumor treatment : Cellular and Molecular Biology Letters uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Cellular and Molecular Biology Letters

Editor-in-Chief: /

Impact Factor 2014: 1.593
5-year IMPACT FACTOR: 1.647

SCImago Journal Rank (SJR) 2014: 0.670
Source Normalized Impact per Paper (SNIP) 2014: 0.620
Impact per Publication (IPP) 2014: 1.843


Toll-like receptors and their role in carcinogenesis and anti-tumor treatment

1Department of Hematology, Medical University of Łódź, Ciołkowskiego 2, 93-513, Łódź, Poland

© 2008 University of Wrocław, Poland. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Cellular and Molecular Biology Letters. Volume 14, Issue 2, Pages 248–272, ISSN (Online) 1689-1392, DOI: 10.2478/s11658-008-0048-z, March 2009

Publication History

Published Online:


Toll-like receptors (TLRs) have been described as major components of the innate immune system, recognizing the conserved molecular structures found in the large groups of pathogens called pathogen-associated molecular patterns (PAMPs). TLR expression is ubiquitous, from epithelial to immunocompetent cells. TLR ligation triggers several adapter proteins and downstream kinases, leading to the induction of key pro-inflammatory mediators but also anti-inflammatory and anti-tumor cytokines. The result of this activation goes beyond innate immunity to shape the adaptive responses against pathogens and tumor cells, and maintains host homeostasis via cell debris utilization. TLRs have already become potent targets in infectious disease treatment and vaccine therapy and in neoplastic disease treatment, due to their ability to enhance antigen presentation. However, some studies show the dual effect of TLR stimulation on malignant cells: they can be proapoptotic or promote survival under different conditions. It is therefore crucial to design further studies assessing the biology of these receptors in normal and transformed cells. The established role of TLRs in human disease therapy is based on TLR7 and TLR4 agonists, respectively for the novel treatment of some types of skin cancer and for the anti-hepatitis B virus vaccine. Some clinical trials involving TLR agonists as potent enhancers of the anti-tumor response in solid tumors have begun.

Keywords: Toll-like receptors; Innate immunity; Treatment; Carcinogenesis; Tumor; Vaccine; Dendritic cells

  • [1] Myeong, S.L. and Young-Joon, K. Pattern-recognition receptor signaling initiated from extracellular, membrane, and cytoplasmic space. Mol. Cells 23 (2007) 1–10.

  • [2] Anderson, K.V., Jurgens, G. and Nusslein-Volhard, C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42 (1995) 779–789.

  • [3] Rosetto, M., Engström, Y., Baldari, C.T., Telford, J.L. and Hultmark, D. Signals from the IL-1 receptor homolog, Toll, can activate an immune response in a Drosophila hemocyte cell line. Biochem. Biophys. Res. Commun. 209 (1995) 111–116.

  • [4] Gay, N.J. and Keith, F.J. Drosophila Toll and IL-1 receptor. Nature 351 (1991) 355–356.

  • [5] Medzhitov, R., Preston-Hurlburt, P. and Janeway, C.A.Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394.

  • [6] Hopkins, P.A. and Sriskandan, S. Mammalian Toll-like receptors: to immunity and beyond. Clin. Exp. Immunol. 140 (2005) 395–407.

  • [7] Bell, J.K., Mullen, G.E., Leifer, C.A., Mazzoni, A., Davies, D.R. and Segal, D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 24 (2003) 528–533. [CrossRef]

  • [8] Ozinsky, A., Underhill, D.M., Fontenot, J.D., Hajjar, A.M., Smith, K.D., Wilson, C.B., Schroeder, L. and Aderem, A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 97 (2000) 13766–13771. [CrossRef]

  • [9] Meng, G., Grabiec, A., Vallon, M., Ebe, B., Hampel, S., Bessler, W., Wagner, H. and Kirschning, C.J. Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2. J. Biol. Chem. 278 (2003) 39822–39829.

  • [10] Roach, J.C., Glusman, G., Rowen, L., Kaur, A., Purcell, M.K., Smith, K.D., Hood, L.E. and Aderem, A. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. USA 102 (2005) 9577–9582. [CrossRef]

  • [11] Takeuchi, O., Kawai, T., Mühlradt, P.F., Morr, M., Radolf, J.D., Zychlinsky, A., Takeda, K. and Akira, S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13 (2001) 933–940. [CrossRef]

  • [12] Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R.L. and Akira, S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169 (2002) 10–14.

  • [13] Iwaki, D., Mitsuazawa, H. and Murakami, S. The extracellular toll-like receptor 2 domain directly binds peptidoglycan derived from Staphylococcus aureus. J. Biol. Chem. 277 (2002) 24315–24320.

  • [14] Means, T.K., Lien, E., Yoshimura, A., Wang, S., Golenbock, D.T. and Fenton, M.J. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163 (1999) 6748–6755.

  • [15] Gantner, B.N., Simmons, R.M., Canavera, S.J., Akira, S. and Underhill, D.M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197 (2003) 1107–1117.

  • [16] Alexopoulou, L., Holt, A.C., Medzhitov, R. and Flavell, R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732–738.

  • [17] Matsukura, S., Kokubu, F., Kurokawa, M., Kawaguchi, M., Ieki, K., Kuga, H., Odaka, M., Suzuki, S., Watanabe, S., Takeuchi, H., Kasama, T. and Adachi, M. Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clin. Exp. Allergy 36 (2006) 1049–1062. [CrossRef]

  • [18] Yang, H., Young, D.W., Gusovsky, F. and Chow, J.C. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J. Biol. Chem. 275 (2002) 20861–20866.

  • [19] Rallabhandi, P., Bell, J., Boukhvalova, M.S., Medvedev, A., Lorenz, E., Arditi, M., Hemming, V.G., Blanco, J.C., Segal, D.M. and Vogel, S.N. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J. Immunol. 177 (2006) 322–332.

  • [20] Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., Eng, J.K., Akira, S., Underhill, D.M. and Aderem, A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001) 1099–1103.

  • [21] Smith, K.D., Andersen-Nissen, E., Hayashi, F., Strobe, K., Bergman, M.A., Barrett, S.L., Cookson, B.T. and Aderem, A. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4 (2003) 1247–1253.

  • [22] Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H. and Bauer, S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526–1529.

  • [23] Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A.M., Wagner, H., Lipford, G. and Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3 (2002) 499.

  • [24] Heil, F., Ahmad-Nejad, P., Hemmi, H., Hochrein, H., Ampenberger, F., Gellert, T., Dietrich, H., Lipford, G., Takeda, K., Akira, S., Wagner, H. and Bauer, S. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33 (2003) 2987–2997. [CrossRef]

  • [25] Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K. and Akira, S. A Tolllike receptor recognizes bacterial DNA. Nature 408 (2000) 740–745.

  • [26] Jurk, M. and Vollmer, J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 21 (2007) 387–401. [CrossRef]

  • [27] Li, M., Carpio, D.F., Zheng, Y., Bruzzo, P., Singh, V., Ouaaz, F., Medzhitov, R.M. and Beg, A.A. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166 (2001) 7128–7135.

  • [28] Basu, S., Binder, R.J., Suto, R., Anderson, K.M. and Srivastava, P.K. Necrotic but not apoptotic cell death releases heat Shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12 (2000) 1539–1546. [CrossRef]

  • [29] Wang, Y., Kelly, C.G., Singh, M., McGowan, E.G., Carrara, A.S., Bergmeier, L.A. and Lehner, T. Stimulation of Th1-polarizing cytokines, CC chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat Shock protein 70. J. Immunol. 169 (2002) 2422–2429.

  • [30] Abulafia-Lapid, R., Elias, D., Raz, I., Keren-Zur, Y., Atlan, H. and Cohen, I.R. T-cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J. Autoimmun. 12 (1999) 121–129. [CrossRef]

  • [31] Szewczuk, M.R. and Depew, W.T. Evidence for T lymphocyte reactivity to the 65 kilodalton heat Shock protein of mycobacterium in active Crohn’s disease. Clin. Invest. Med. 15 (1992) 494–505.

  • [32] Bausinger, H., Lipsker, D., Ziylan, U., Manié, S., Briand, J.P., Cazenave, J.P., Muller, S., Haeuw, J.F., Ravanat, C., de la Salle, H. and Hanau, D. Endotoxin-free heat-Shock protein 70 fails to induce APC activation. Eur. J. Immunol. 32 (2002) 3708–3713. [CrossRef]

  • [33] Gao, B. and Tsan, M.F. Recombinant human heat Shock protein 60 does not induce the release of tumor necrosis factor alpha from murine macrophages. J. Biol. Chem. 278 (2003) 22523–22529. [CrossRef]

  • [34] Kariko, K., Ni, H., Capodici, J., Lamphier, M. and Weissman, D. mRNA is an endogenous ligand for toll-like receptor 3. J. Biol. Chem. 279 (2004) 12542–12550.

  • [35] Kowalski, M.L., Wolska, A., Grzegorczyk, J., Hilt, J., Jarzebska, M., Drobniewski, M., Synder, M. and Kurowski, M. Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediators Inflamm. (2008) 132732.

  • [36] Kawai, T. and Akira, S. TLR signaling. Cell Death Differ. 13 (2006) 816–825.

  • [37] Bjorkbacka, H., Fitzgerald, K.A., Huet, F., Li X., Gregory, J.A., Lee, M.A., Ordija, C.M., Dowley, N.E., Golenbock, D.T. and Freeman, M.W. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol. Genomics 19 (2004) 319–330. [CrossRef]

  • [38] Zhao, J. and Wu, X.Y. Triggering of toll-like receptors 2 and 4 by Aspergillus fumigatus conidia in immortalized human corneal epithelial cells to induce inflammatory cytokines. Chin. Med. J. (Engl). 121 (2008) 450–454.

  • [39] Covert, M.W., Leung, T.H., Gaston, J.E. and Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309 (2005) 1854–1857.

  • [40] Wang, J.E., Jorgensen, P.F., Almlof, M., Thiemermann, C., Foster, S.J., Aasen, A.O. and Solberg, R. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect. Immun. 68 (2000) 3965–3670. [CrossRef]

  • [41] Ellingsen, E., Morath, S., Flo, T., Schromm, A., Hartung, T., Thiemermann, C., Espevik, T., Golenbock, D., Foster, D., Solberg, R., Aasen, A. and Wang, J. Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med. Sci. Monit. 8 (2002) BR149–156.

  • [42] Wang, J.P., Kurt-Jones, E.A., Shin, O.S., Manchak, M.D., Levin, M.J. and Finberg, R.W. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J. Virol. 79 (2005) 12658–12666. [CrossRef]

  • [43] Smith, M.F.Jr, Mitchell, A., Li, G., Ding, S., Fitzmaurice, A.M., Ryan, K., Crowe, S. and Goldberg, J.B. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J. Biol. Chem. 278 (2003) 32552–32560.

  • [44] Gaudreault, E., Fiola, S., Olivier, M. and Gosselin, J. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J. Virol. 81 (2007) 8016–8024.

  • [45] Hertz, C.J., Wu, Q., Porter, E.M., Zhang, Y.J., Weismuller, K.H., Godowski, P.J., Ganz, T., Randell, S.H. and Modlin, R.L. Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J. Immunol. 171 (2003) 6820–6826.

  • [46] Alexopolou, L., Holt, A.C., Medzhitov, R. and Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 413 (2001) 732–738.

  • [47] Guillot, L., Le Goffic, R., Bloch, S., Escriou, N., Akira, S., Chignard, M. and Si-Tahar, M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J. Biol. Chem. 280 (2005) 5571–5580.

  • [48] Li, Q., Withoff, S. and Verma, I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 26 (2005) 318–325. [CrossRef]

  • [49] Balkwill, F. and Coussens, L.M. Cancer: an inflammatory link. Nature 431 (2004) 405–406.

  • [50] Gupta, R.A. and Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1 (2001) 11–21. [CrossRef]

  • [51] Robak, P., Smolewski, P. and Robak, T. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk. Lymphoma 49 (2008) 1452–1462. [CrossRef]

  • [52] Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E. and Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461–466.

  • [53] Palayoor, S.T., Youmell, M.Y., Calderwood, S.K., Coleman, C.N. and Price, B.D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18 (1999) 7389–7394. [CrossRef]

  • [54] Baron, F., Turhan, A.G., Giron-Michel, J., Azzarone, B., Bentires-Alj, M., Bours, V., Bourhis, J.H., Chouaib, S. and Caignard, A. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99 (2002) 2107–2113. [CrossRef]

  • [55] Griffin, J.D. Leukemia stem cells and constitutive activation of NF-kappaB. Blood 98 (2001) 2291. [CrossRef]

  • [56] Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J. and Siegel, D.S. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93 (1999) 3044–3052.

  • [57] Philip, M., Rowley, D.A. and Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 14 (2004) 433–439. [CrossRef]

  • [58] Chang, Y.J., Wu, M.S., Lin, J.T. and Chen, C.C. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J. Immunol. 175 (2005) 8242–8252.

  • [59] Li, V.W., Li, W.W., Talcott, K.E. and Zhai, A.W. Imiquimod as an antiangiogenic agent. J. Drugs Dermatol. 4 (2005) 708–717.

  • [60] Majewski, S., Marczak, M., Mlynarczyk, B., Benninghoff, B. and Jablonska, S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int. J. Dermatol. 44 (2005) 14–19. [CrossRef]

  • [61] Damiano, V., Caputo, R., Bianco, R., D’Armiento, F.P., Leonardi, A., De Placido, S., Bianco, A.R., Agrawal, S., Ciardiello, F. and Tortora, G. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin. Cancer Res. 12 (2006) 577–583. [CrossRef]

  • [62] Fukata, M., Chen, A., Vamadevan, A.S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A.J., Subbaramaiah, K., Cooper, H.S., Itzkowitz, S.H. and Abreu, M.T. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133 (2007) 1869–1881.

  • [63] Swann, J.B., Vesely, M.D., Silva, A., Sharkey, J., Akira, S., Schreiber, R.D. and Smyth, M.J. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. USA 105 (2008) 652–656. [CrossRef]

  • [64] Kundu, S.D., Leem, C., Billips, B.K., Habermacher, G.M., Zhang, Q., Liu, V., Wong, L.Y., Klumpp, D.J. and Thumbikat, P. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68 (2008) 223–229. [CrossRef]

  • [65] Pries, R., Hogrefe, L., Xie, L., Frenzel, H., Brocks, C., Ditz, C. and Wollenberg, B. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int. J. Mol. Med. 21 (2008) 209–215.

  • [66] Jego, G., Bataille, R., Geffroy-Luseau, A., Descamps, G. and Pellat-Deceunynck, C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20 (2006) 1130–1137. [CrossRef]

  • [67] Chochi, K., Ichikura, T., Kinoshita, M., Majima, T., Shinomiya, N., Tsujimoto, H., Kawabata, T., Sugasawa, H., Ono, S., Seki, S. and Mochizuki, H. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin. Cancer Res. 14 (2008) 2909–2917. [CrossRef]

  • [68] Paone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E. and Riccioli, A. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29 (2008) 1334–1342. [CrossRef]

  • [69] Barnhart, B.C. and Peter, M.E. The TNF receptor 1: a split personality complex. Cell 114 (2003) 148–150. [CrossRef]

  • [70] Jahrsdörfer, B., Wooldridge, J.E., Blackwell, S.E., Taylor, C.M., Griffith, T.S., Link, B.K. and Weiner, G.J. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 77 (2005) 378–387.

  • [71] Jahrsdörfer, B., Jox, R., Mühlenhoff, L., Tschoep, K., Krug, A., Rothenfusser, S., Meinhardt, G., Emmerich, B., Endres, S. and Hartmann, G. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol. 72 (2002) 83–92.

  • [72] Smits, E.L., Ponsaerts, P., Van de Velde, A.L., Van Driessche, A., Cools, N., Lenjou, M., Nijs, G., Van Bockstaele, D.R., Berneman, Z.N. and Van Tendeloo, V.F. Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia 21 (2007) 1691–1699. [CrossRef]

  • [73] Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D. and Romero, P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13 (2007) 4565–4574. [CrossRef]

  • [74] Lehner, M., Bailo, M., Stachel, D., Roesler, W., Parolini, O. and Holter, W. Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha. Leuk. Res. 31 (2007) 1729–1735. [CrossRef]

  • [75] Haase, R., Kirschning, C.J., Sing, A., Schröttner, P., Fukase, K., Kusumoto, S., Wagner, H., Heesemann, J. and Ruckdeschel, K. A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J. Immunol. 171 (2003) 4294–4303.

  • [76] Hsu, L.C., Park, J.M., Zhang, K., Luo, J.L., Maeda, S., Kaufman, R.J., Eckmann, L., Guiney, D.G. and Karin, M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428 (2004) 341–345.

  • [77] Into, T., Kiura, K., Yasuda, M., Kataoka, H., Inoue, N., Hasebe, A., Takeda, K., Akira, S. and Shibata, K. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell. Microbiol. 6 (2004) 187–199.

  • [78] Jung, D.Y., Lee, H., Jung, B.Y., Ock, J., Lee, M.S., Lee, W.H. and Suk, K. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J. Immunol. 174 (2005) 6467–6476.

  • [79] Ma, Y., Liu, H., Tu-Rapp, H., Thiesen, H.J., Ibrahim, S.M., Cole, S.M. and Pope, R.M. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat. Immunol. 5 (2004) 380–387.

  • [80] Imtiyaz, H.Z., Rosenberg, S., Zhang, Y., Rahman, Z.S., Hou, Y.J., Manser, T. and Zhang, J. The Fas-associated death domain protein is required in apoptosis and TLR-induced proliferative responses in B cells. J. Immunol. 176 (2006) 6852–6861.

  • [81] Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.A., Abrahams, V.M., Chan, S., Visintin, I., Rutherford, T. and Mor, G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66 (2006) 3859–3868. [CrossRef]

  • [82] Bottero, V., Busuttil, V., Loubat, A., Magné, N., Fischel, J.L., Milano, G. and Peyron, J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 61 (2001) 7785–7791.

  • [83] Tosi, P., Zinzani, P.L., Pellacani, A., Ottaviani, E., Magagnoli, M. and Tura, S. Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells. Leuk. Lymphoma 26 (1997) 343–348.

  • [84] Pellacani, A., Tosi, P., Zinzani, P.L., Ottaviani, E., Albertini, P., Magagnoli, M. and Tura, S. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk. Lymphoma 33 (1999) 147–153.

  • [85] Shi, Y., White, D., He, L., Miller, R.L. and Spaner, D.E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 67 (2007) 1823–1831.

  • [86] Garay, R.P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J.F. and Chiavaroli, C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. 563 (2007) 1–17.

  • [87] Coussens, L.M. and Werb, Z. Inflammation and cancer. Nature. 420 (2002) 860–867.

  • [88] Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531–562. [CrossRef]

  • [89] Fisson, S., Darrasse-Jèze, G., Litvinova, E., Septier, F., Klatzmann, D., Liblau, R. and Salomon, B.L. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198 (2003) 737–746.

  • [90] Singh, B., Read, S., Asseman, C., Malmström, V., Mottet, C., Stephens, L.A., Stepankova, R., Tlaskalova, H. and Powrie, F. Control of intestinal inflammation by regulatory T cells. Immunol Rev. 182 (2001) 190–200.

  • [91] Hori, S., Carvalho, T.L. and Demengeot, J. CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur. J. Immunol. 32 (2002) 1282–1291. [CrossRef]

  • [92] Hänig, J. and Lutz, M.B. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J. Immunol. 180 (2008) 1405–1413. [CrossRef]

  • [93] Caramalho, I., Lopes-Carvalho, T., Ostler, D., Zelenay, S., Haury, M. and Demengeot, J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197 (2003) 403–411.

  • [94] Sfondrini, L., Rossini, A., Besusso, D., Merlo, A., Tagliabue, E., Mènard, S. and Balsari, A. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176 (2006) 6624–6630.

  • [95] Peng, G., Guo, Z., Kiniwa, Y., Voo, K.S., Peng, W., Fu, T., Wang, D.Y., Li, Y., Wang, H.Y. and Wang, R.F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005) 1380–1384.

  • [96] Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I. and Lanzavecchia, A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189 (1999) 821–829.

  • [97] Pulendran, B., Kumar, P., Cutler, W., Mohamadzadeh, M., Van Dyke, T. and Banchereau, J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167 (2001) 5067–5076.

  • [98] Pasare, C. and Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033–1036.

  • [99] Spaner, D.E., Shi, Y., White, D., Mena, J., Hammond, C., Tomic, J., He, L., Tomai, M.A., Miller, R.L., Booth, J. and Radvanyi, L. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20 (2006) 286–295.

  • [100] Tomic, J., White, D., Shi, Y., Mena, J., Hammond, C., He, L., Miller, R.L. and Spaner, D.E. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J. Immunol. 176 (2006) 3830–3839.

  • [101] Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G.B., Wagner, H. and Peschel, C. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95 (2000) 999–1006.

  • [102] Decker, T., Schneller, F., Kronschnabl, M., Dechow, T., Lipford, G.B., Wagner, H. and Peschel, C. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp. Hematol. 28 (2000) 558–568. [CrossRef]

  • [103] Decker, T., Hipp, S., Kreitman, R.J., Pastan, I., Peschel, C., Licht, T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 99 (2002) 1320–1326.

  • [104] Evel-Kabler, K., Song, X.T., Aldrich, M., Huang, X.F. and Chen, S.Y. SOCS1 restricts dendritic cells’ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116 (2006) 90–100.

  • [105] Tormo, D., Ferrer, A., Bosch, P., Gaffal, E., Basner-Tschakarjan, E., Wenzel, J. and Tüting, T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66 (2006) 5427–5435. [CrossRef]

  • [106] Wysocka, M., Benoit, B.M., Newton, S., Azzoni, L., Montaner, L.J. and Rook, A.H. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104 (2004) 4142–4149. [CrossRef]

  • [107] Mangsbo, S.M., Ninalga, C., Essand, M., Loskog, A. and Tötterman, T.H. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J. Immunother. 31 (2008) 34–42. [CrossRef]

  • [108] Ren, T., Wen, Z.K., Liu, Z.M., Qian, C., Liang, Y.J., Jin, M.L., Cai, Y.Y. and Xu, L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest. 26 (2008) 448–455. [CrossRef]

  • [109] Roda, J.M., Parihar, R. and Carson, W.E.3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 175 (2005) 1619–1627.

  • [110] Frankenberger, M., Pechumer, H. and Ziegler-Heitbrock, H.W. Interleukin-10 is upregulated in LPS tolerance. J. Inflamm. 45 (1995) 56–63.

  • [111] Tominaga, K., Saito, S., Matsuura, M. and Nakano, M. Lipopolysaccharide tolerance in murine peritoneal macrophages induces downregulation of the lipopolysaccharide signal transduction pathway through mitogen-activated protein kinase and nuclear factor-kappaB cascades, but not lipopolysaccharide-incorporation steps. Biochim. Biophys. Acta 1450 (1999) 130–144.

  • [112] Medvedev, A.E., Kopydlowski, K.M. and Vogel, S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J. Immunol. 164 (2000) 5564–5574.

  • [113] Nomura, F., Akashi, S., Sakao, Y., Sato, S., Kawai, T., Matsumoto, M., Nakanishi, K., Kimoto, M., Miyake, K., Takeda, K. and Akira, S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J. Immunol. 164 (2000) 3476–3479.

  • [114] Hume, D.A., Underhill, D.M., Sweet, M.J., Ozinsky, A.O., Liew, F.Y. and Aderem, A. Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state. BMC Immunol. 2 (2001) 11. [CrossRef]

  • [115] Randow, F., Syrbe, U., Meisel, C., Krausch, D., Zuckermann, H., Platzer, C. and Volk, H.D. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181 (1995) 1887–1892.

  • [116] Hamdy, S., Molavi, O., Ma, Z., Haddadi, A., Alshamsan, A., Gobti, Z., Elhasi, S., Samuel, J. and Lavasanifar, A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity. Vaccine 26 (2008) 5046–5057. [CrossRef]

  • [117] Ramakrishna, V., Vasilakos, J.P., Tario, J.D.Jr, Berger, M.A., Wallace, P.K. and Keler, T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J. Transl. Med. 5 (2007) 5. [CrossRef]

  • [118] den Brok, M.H., Sutmuller, R.P., Nierkens, S., Bennink, E.J., Toonen, L.W., Figdor, C.G., Ruers, T.J. and Adema, G.J. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 66 (2006) 7285–7292. [CrossRef]

  • [119] Koido, S., Hara, E., Homma, S., Torii, A., Toyama, Y., Kawahara, H., Watanabe, M., Yanaga, K., Fujise, K., Tajiri, H., Gong, J. and Toda, G. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11 (2005) 7891–7900. [CrossRef]

  • [120] Adams, S., O’Neill, D.W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C.M., Angiulli, A., Angiulli, F., Ritter, E., Holman, R.M., Shapiro, R.L., Berman, R.S., Berner, N., Shao. Y., Manches, O., Pan, L., Venhaus, R.R., Hoffman, E.W., Jungbluth, A., Gnjatic, S., Old, L., Pavlick, A.C. and Bhardwaj, N. Immunization of malignant melanoma patients with fulllength NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181 (2008) 776–784.

  • [121] Lesimple, T., Neidhard, E.M., Vignard, V., Lefeuvre, C., Adamski, H., Labarrière, N., Carsin, A., Monnier, D., Collet, B., Clapissonm G., Birebent, B., Philip, I., Toujas, L., Chokri, M. and Quillien, V. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin. Cancer Res. 12 (2006) 7380–7388. [CrossRef]

  • [122] Speiser, D.E., Liénard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A.M., Cerottini, J.C. and Romero, P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005) 739–746.

  • [123] Shackleton, M., Davis, I.D., Hopkins, W., Jackson, H., Dimopoulos, N., Tai, T., Chen, Q., Parente, P., Jefford, M., Masterman, K.A., Caron, D., Chen, W., Maraskovsky, E. and Cebon, J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4 (2004) 9.

  • [124] Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A.M. and Leichman, C.G. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 3979–3986.

  • [125] Dummer, R., Hauschild, A., Becker, J.C., Grob, J.J., Schadendorf, D., Tebbs, V., Skalsky, J., Kaehler, K.C., Moosbauer, S., Clark, R., Meng, T.C. and Urosevic, M. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14 (2008) 856–864.

  • [126] Pashenkov, M., Goëss, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., Britten, C.M., Smolle, J., Koller, S., Mauch, C., Tantcheva-Poor, I., Grabbe, S., Loquai, C., Esser, S., Franckson, T., Schneeberger, A., Haarmann, C., Krieg, A.M., Stingl, G. and Wagner, S.N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24 (2006) 5716–5724. [CrossRef]

  • [127] Schmidt, J., Welsch, T., Jäger, D, Mühlradt, P.F., Büchler, M.W., Märten, A. Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial. Br. J. Cancer 97 (2007) 598–604.

  • [128] Link, B.K., Ballas, Z.K., Weisdorf, D., Wooldridge, J.E., Bossler, A.D., Shannon, M., Rasmussen, W.L., Krieg, A.M. and Weiner, G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29 (2006) 558–568.

  • [129] Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., Puybasset. L., Van Effenterre, R., Delattre, J.Y. and Carpentier, A.F. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro- Oncol. 8 (2006) 60–66.

  • [130] Leonard, J.P., Link, B.K., Emmanouilides, C., Gregory, S.A., Weisdorf, D., Andrey, J., Hainsworth, J., Sparano, J.A., Tsai, D.E., Horning, S., Krieg, A.M. and Weiner, G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin’s lymphoma. Clin. Cancer Res. 13 (2007) 6168–6174. [CrossRef]

  • [131] Friedberg, J.W., Kim, H., McCauley, M., Hessel, E.M., Sims, P., Fisher, D.C., Nadler, L.M., Coffman, R.L. and Freedman, A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 (2005) 489–495.

  • [132] Spaner, D.E., Miller, R.L., Mena, J., Grossman, L., Sorrenti, V. and Shi, Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphoma 46 (2005) 935–939.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Michele Ammendola, Rosa Patruno, Rosario Sacco, Ilaria Marech, Giuseppe Sammarco, Valeria Zuccalà, Maria Luposella, Nicola Zizzo, Claudia Gadaleta, Mariangela Porcelli, Cosmo Damiano Gadaleta, Domenico Ribatti, and Girolamo Ranieri
Expert Opinion on Therapeutic Targets, 2016, Page 1
Alessio Paone, Roberta Galli, Chiara Gabellini, Dmitriy Lukashev, Donatella Starace, Agnes Gorlach, Paola De Cesaris, Elio Ziparo, Donatella Del Bufalo, Michail V. Sitkovsky, Antonio Filippini, and Anna Riccioli
Neoplasia, 2010, Volume 12, Number 7, Page 539
Sonia Podvin, Xitong Dang, Morgan Meads, Arwa Kurabi, Todd Costantini, Brian P. Eliceiri, Andrew Baird, and Raul Coimbra
Inflammation Research, 2015, Volume 64, Number 2, Page 107
Krishan K. Thakur, Nityanand B. Bolshette, Cristiana Trandafir, Vinayak S. Jamdade, Alexandru Istrate, Ranadeep Gogoi, and Andrei Cucuianu
Experimental Hematology, 2015, Volume 43, Number 3, Page 158
U. Chandola, R. Das, and B. Panda
Briefings in Functional Genomics, 2015, Volume 14, Number 3, Page 169
Fatma E. Mohamed, Rajai M. Al-Jehani, Shane S. Minogue, Fausto Andreola, Alison Winstanley, Steven W.M. Olde Damink, Abeba Habtesion, Massimo Malagó, Nathan Davies, Tu Vinh Luong, Amar P. Dhillon, Rajeshwar P. Mookerjee, Dipok K. Dhar, and Rajiv Jalan
Liver International, 2015, Volume 35, Number 3, Page 1063
Shanjana Awasthi
Frontiers in Immunology, 2014, Volume 5
Tatjana Eigenbrod and Alexander H. Dalpke
JAK-STAT, 2013, Volume 2, Number 1, Page e23011
Ju-Hee Han, Shin-Young Park, Jin-Bum Kim, Sung-Dae Cho, Bumseok Kim, Bo-Yeon Kim, Min-Jung Kang, Dong-Jae Kim, Jae-Hak Park, and Jong-Hwan Park
American Journal of Reproductive Immunology, 2013, Volume 70, Number 4, Page 317
Shi-Xiang Zhou, Feng-Sheng Li, Yu-Lei Qiao, Xue-Qing Zhang, and Zhi-Dong Wang
Asian Pacific Journal of Cancer Prevention, 2012, Volume 13, Number 6, Page 2807
Lijuan Wang, Yi Zhao, Jianfei Qian, Luhong Sun, Yong Lu, Haiyan Li, Yi Li, Jing Yang, Zhen Cai, and Qing Yi
Cancer, 2013, Volume 119, Number 4, Page 782
J Noack, M Jordi, L Zauner, D Alessi, A Burch, M Tinguely, M Hersberger, M Bernasconi, and D Nadal
Cell Death and Disease, 2012, Volume 3, Number 6, Page e323
Mee-Young Ahn, Seong-Min Kwon, Hak Hyun Cheong, Jong-Hwan Park, Jun Lee, Seung-Ki Min, Sang-Gun Ahn, and Jung-Hoon Yoon
Journal of Oral Pathology & Medicine, 2012, Page no
Konstantinos E. Tsimogiannis, Constantinos C. Tellis, Alexandros D. Tselepis, George K. Pappas-Gogos, Evangelos C. Tsimoyiannis, and George Basdanis
Surgical Endoscopy, 2012, Volume 26, Number 2, Page 330
Silan Liu, Jianping Yang, Lina Wang, Miao Jiang, Qiaocheng Qiu, Zhenni Ma, Lei Liu, Caifang Li, Chunguang Ren, Jin Zhou, and Wei Li
Brain Research, 2010, Volume 1346, Page 213
Nicholas Butowski
Neurosurgery Clinics of North America, 2010, Volume 21, Number 1, Page 53
Bao Lam, Patrick A Ott, and Anna C Pavlick
Aging Health, 2010, Volume 6, Number 3, Page 383
Jong-Hwan Park, Hyo-Eun Yoon, Dong-Jae Kim, Soo-A Kim, Sang-Gun Ahn, and Jung-Hoon Yoon
Journal of Oral Pathology & Medicine, 2011, Volume 40, Number 2, Page 187
Salomé González-Reyes, Jesús M. Fernández, Luis O. González, Alina Aguirre, Aurelio Suárez, José M. González, Safwan Escaff, and Francisco J. Vizoso
Cancer Immunology, Immunotherapy, 2011, Volume 60, Number 2, Page 217
Jong-Hwan Park, Hyo-Eun Yoon, Do-In Jeon, Sang-Gun Ahn, and Jung-Hoon Yoon
Journal of Oral Pathology & Medicine, 2010, Volume 39, Number 10, Page 781
Tamas Fulop, Rami Kotb, Carl F. Fortin, Graham Pawelec, Flavia De Angelis, and Anis Larbi
Annals of the New York Academy of Sciences, 2010, Volume 1197, Number 1, Page 158
Julie L. Jordan, A. Nowak, and T. D. G. Lee
Cancer Immunology, Immunotherapy, 2010, Volume 59, Number 5, Page 789

Comments (0)

Please log in or register to comment.